SVB Securities analyst Thomas Smith reiterated a Buy rating on MannKind (MNKD – Research Report) on September 6. The company’s shares closed last Friday at $3.88.
According to TipRanks, Smith is an analyst with an average return of -10.5% and a 36.61% success rate. Smith covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Prometheus Biosciences, and Provention Bio.
MannKind has an analyst consensus of Moderate Buy, with a price target consensus of $5.00.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $5.44 and a one-year low of $2.49. Currently, MannKind has an average volume of 4.63M.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MNKD in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MannKind Corp. is a biopharmaceutical company. It focuses on the discovery, development and, commercialization of therapeutic products for diseases, such as diabetes and cancer. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Westlake Village, CA.
Read More on MNKD:
- BTIG Sticks to Their Buy Rating for Scorpio Tankers (STNG)
- JMP Securities Reaffirms Their Buy Rating on Incyte (INCY)
- SVB Securities Sticks to Its Hold Rating for Gilead Sciences (GILD)
- Regeneron (REGN) Receives a Hold from SVB Securities
- SVB Securities Sticks to Its Buy Rating for Crinetics Pharmaceuticals (CRNX)
